Q4 2018 Adaptimmune Therapeutics PLC Earnings Call Transcript
Good day, ladies and gentlemen, and welcome to the Adaptimmune Therapeutics conference call. (Operator Instructions)
I would now like to introduce your host for today's conference, Juli Miller. You may begin.
Good morning, and welcome to Adaptimmune's conference call to discuss our fourth quarter and full year 2018 financial results and other business updates. We issued a press release earlier this morning, and I would ask you to please review the full text of our forward-looking statements. As a reminder, we anticipate making projections during this call, and actual results could differ materially due to a number of factors.
In addition, I would like to make you aware of an update to our SPEAR T-cell nomenclature. From here forward, we will refer to our SPEAR T-cell's with a prefix, ADP for our company name, followed by a reference to the HLA-type specific for the SPEAR T-cell, which is currently A2 for all of our trials and then a reference to the target antigen.
So
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
